N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice

[1]  S. Cuzzocrea,et al.  Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson’s Disease , 2017, Molecular Neurobiology.

[2]  C. Franceschi,et al.  Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis , 2018, Free radical biology & medicine.

[3]  Zishan Wang,et al.  Long-term Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson’s Disease , 2018, Neuroscience.

[4]  N. Jamali-Raeufy,et al.  The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling , 2017, Experimental Gerontology.

[5]  M. L. Fravolini,et al.  Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using 123I-FP-CIT brain SPET data by using an artificial neural network classifier, a classification tree (ClT). , 2017, Hellenic journal of nuclear medicine.

[6]  S. Cuzzocrea,et al.  KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice , 2017, Molecular Neurobiology.

[7]  S. Cuzzocrea,et al.  Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia , 2017, Front. Neurol..

[8]  S. Cuzzocrea,et al.  Beneficial Effects of Co‐Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism , 2017, CNS neuroscience & therapeutics.

[9]  M. T. Pellecchia,et al.  The non‐motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4‐year longitudinal study , 2016, European journal of neurology.

[10]  N. Mori,et al.  Human behavioral assessments in current research of Parkinson’s disease , 2016, Neuroscience & Biobehavioral Reviews.

[11]  H. Onoe,et al.  Animal behavioral assessments in current research of Parkinson’s disease , 2016, Neuroscience & Biobehavioral Reviews.

[12]  N. Chattipakorn,et al.  Acetylcholine Attenuates Hydrogen Peroxide-Induced Intracellular Calcium Dyshomeostasis Through Both Muscarinic and Nicotinic Receptors in Cardiomyocytes , 2016, Cellular Physiology and Biochemistry.

[13]  S. Park,et al.  Diaminodiphenyl sulfone–induced parkin ameliorates age-dependent dopaminergic neuronal loss , 2016, Neurobiology of Aging.

[14]  Pallav Sengupta,et al.  Men and mice: Relating their ages. , 2016, Life sciences.

[15]  S. Cuzzocrea,et al.  The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model. , 2015, CNS & neurological disorders drug targets.

[16]  Jing Xu,et al.  Tiagabine Protects Dopaminergic Neurons against Neurotoxins by Inhibiting Microglial Activation , 2015, Scientific Reports.

[17]  Manuel Rodriguez,et al.  Parkinson's disease as a result of aging , 2015, Aging cell.

[18]  H. Berendse,et al.  Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume , 2015, Movement disorders : official journal of the Movement Disorder Society.

[19]  Chris Bye,et al.  Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. , 2014, Brain : a journal of neurology.

[20]  M. Beckstead,et al.  Aging Decreases L-Type Calcium Channel Currents and Pacemaker Firing Fidelity in Substantia Nigra Dopamine Neurons , 2014, The Journal of Neuroscience.

[21]  S. Cuzzocrea,et al.  Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. , 2013, CNS & neurological disorders drug targets.

[22]  D. Passarella,et al.  Microtubule Alterations Occur Early in Experimental Parkinsonism and The Microtubule Stabilizer Epothilone D Is Neuroprotective , 2013, Scientific Reports.

[23]  E. Mazzon,et al.  Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease , 2012, PloS one.

[24]  Subhojit Roy,et al.  α-Synuclein Inhibits Intersynaptic Vesicle Mobility and Maintains Recycling-Pool Homeostasis , 2012, The Journal of Neuroscience.

[25]  D. German,et al.  Apoptosis Signal-Regulating Kinase 1 Mediates MPTP Toxicity and Regulates Glial Activation , 2012, PloS one.

[26]  P. Piazza,et al.  Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain , 2012, PAIN.

[27]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[28]  E. Mazzon,et al.  Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury , 2011, Brain, Behavior, and Immunity.

[29]  R. Wood,et al.  MPTP Neurotoxicity and Testosterone Induce Dendritic Remodeling of Striatal Medium Spiny Neurons in the C57Bl/6 Mouse , 2011, Parkinson's disease.

[30]  Erik Maronde,et al.  Palmitoylethanolamide Protects Dentate Gyrus Granule Cells via Peroxisome Proliferator-Activated Receptor-Alpha , 2011, Neurotoxicity Research.

[31]  H. Hansen.  Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain , 2010, Experimental Neurology.

[32]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[33]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[34]  Yong Lin,et al.  Luteolin, a flavonoid with potential for cancer prevention and therapy. , 2008, Current cancer drug targets.

[35]  R. Elble.  Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[36]  P. Mcgeer,et al.  The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease , 2008, Experimental Neurology.

[37]  F. Gage,et al.  Neurons born in the adult dentate gyrus form functional synapses with target cells , 2008, Nature Neuroscience.

[38]  E. Mazzon,et al.  Effects of Palmitoylethanolamide on Signaling Pathways Implicated in the Development of Spinal Cord Injury , 2008, Journal of Pharmacology and Experimental Therapeutics.

[39]  D. De Filippis,et al.  Cannabinomimetic Control of Mast Cell Mediator Release: New Perspective in Chronic Inflammation , 2008, Journal of neuroendocrinology.

[40]  F. Gage,et al.  Is neurogenesis reparative after status epilepticus? , 2007, Epilepsia.

[41]  E. Esposito,et al.  Non-steroidal anti-inflammatory drugs in Parkinson's disease , 2007, Experimental Neurology.

[42]  Lloyd Demetrius,et al.  Aging in Mouse and Human Systems , 2006, Annals of the New York Academy of Sciences.

[43]  B. Marchetti,et al.  To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? , 2005, Trends in pharmacological sciences.

[44]  Andreas Hald,et al.  Oxidative stress and inflammation in Parkinson's disease: is there a causal link? , 2005, Experimental Neurology.

[45]  P. Sandercock,et al.  Physical Methods for Preventing Deep Vein Thrombosis in Stroke , 2005, The Cochrane database of systematic reviews.

[46]  M. Chesselet,et al.  3,4-Dihydroxyphenylalanine Reverses the Motor Deficits in Pitx3-Deficient Aphakia Mice: Behavioral Characterization of a Novel Genetic Model of Parkinson's Disease , 2005, The Journal of Neuroscience.

[47]  E. Yoshikawa,et al.  Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.

[48]  Jonathan Salcedo,et al.  Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein , 2004, The Journal of Neuroscience.

[49]  J. Schulz.  Neuronal pathology in Parkinson’s disease , 2004, Cell and Tissue Research.

[50]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[51]  G. Becker.  Methoden zur Frühdiagnose des Morbus Parkinson , 2003, Der Nervenarzt.

[52]  P. Mcgeer,et al.  Innate immunity, local inflammation, and degenerative disease. , 2002, Science of aging knowledge environment : SAGE KE.

[53]  C. Fowler,et al.  The palmitoylethanolamide family: a new class of anti-inflammatory agents? , 2002, Current medicinal chemistry.

[54]  G. Cappelletti,et al.  MICROTUBULE ASSEMBLY IS DIRECTLY AFFECTED BY MPP+IN VITRO , 2001, Cell biology international.

[55]  D. Piomelli,et al.  Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. , 2001, European journal of pharmacology.

[56]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[57]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[58]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[59]  A. Członkowska,et al.  Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Immunopharmacology.

[60]  K. Shimoi,et al.  Radioprotective effect of antioxidative flavonoids in γ-ray irradiated mice , 1994 .

[61]  H. Cameron,et al.  Differentiation of newly born neurons and glia in the dentate gyrus of the adult rat , 1993, Neuroscience.

[62]  P. Mulvihill,et al.  Filaments of Lewy bodies contain insoluble cytoskeletal elements. , 1992, The American journal of pathology.

[63]  F. Solomon,et al.  Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubulin and beta-tubulin , 1990, Molecular and cellular biology.

[64]  L. Hartwell,et al.  Dominant effects of tubulin overexpression in Saccharomyces cerevisiae , 1989, Molecular and cellular biology.

[65]  S. File,et al.  Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat , 1985, Journal of Neuroscience Methods.

[66]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[67]  M. Chesselet,et al.  Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[68]  G. Becker.  [Methods for the early diagnosis of Parkinson's disease]. , 2003, Der Nervenarzt.

[69]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[70]  S. Przedborski,et al.  Mechanisms of MPTP toxicity. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[71]  K. Shimoi,et al.  Radioprotective effect of antioxidative flavonoids in gamma-ray irradiated mice. , 1994, Carcinogenesis.

[72]  K. Maclennan,et al.  Intermediate filament-ubiquitin diseases: implications for cell sanitization. , 1989, Biochemical Society symposium.